Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LY573636 sodium as second- or third-line treatment for unresectable or metastatic soft tissue sarcoma
2007-001402-24Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tasisulam in soft tissue sarcoma (STS) and synovial sarcoma (SS), sponsored by Eli Lilly and Company. Primary endpoints: Median progression-free survival and Progression-free survival distribution. Started Apr 2007; status: completed.
02
Drugs
tasisulam
03
Conditions
soft tissue sarcoma (STS)synovial sarcoma (SS)
Beyond the preview
Go deeper on 2007-001402-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001402-24.